A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2013
12/19/2013	WO2013186700A1 Antibody formulation
12/19/2013	WO2013186539A1 Genetically modified schmallenberg virus (sbv) for use as vaccine
12/19/2013	WO2013186409A1 Inactivated mycobacteria for oral use in the prevention of tuberculosis
12/19/2013	WO2013186394A1 Polypeptides for use in the prophylactic treatment of allergic asthma
12/19/2013	WO2013186236A1 Antagonists of il-17 isoforms and their uses
12/19/2013	WO2013186230A1 Pharmaceutical formulation for a therapeutic antibody
12/19/2013	WO2013186178A1 Stimulation of cellular immune response against epstein-barr virus (ebv)
12/19/2013	WO2013185558A1 Polypeptides and antibodies for treating hbv infection and related diseases
12/19/2013	WO2013185552A1 Dual-signal independent chimeric antigen receptor and use thereof
12/19/2013	WO2013185337A1 Edwardsiella tarda mutant strain and application thereof
12/19/2013	WO2013185215A1 Antibodies and conjugates that target misfolded prion protein
12/19/2013	WO2013185181A1 Diagnostic method for diseases characterised by ro/la autoimmunity
12/19/2013	WO2013185177A1 Influenza vaccine
12/19/2013	WO2013185165A1 Cd-52 antibodies and their use in determining and enhancing an immune response in a subject
12/19/2013	WO2013152083A3 Pcv/mycoplasma hyopneumoniae combination vaccine
12/19/2013	WO2013142796A3 Methods of treatments using ctla4 antibodies
12/19/2013	WO2013138259A3 Polypeptides for treating and/or limiting influenza infection
12/19/2013	WO2013098655A9 Vaccines directed against human enteroviruses
12/19/2013	WO2013056122A8 Engineered outer domain (eod) of hiv gp120 and mutants thereof
12/19/2013	US20130337544 Methods and composition for the identification of antibiotics that are not susceptible to antibiotic resistance
12/19/2013	US20130337540 Novel Class of Therapeutic Protein Based Molecules
12/19/2013	US20130337533 Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondins) and/or Wnt
12/19/2013	US20130337048 Method and compositions for treating hiv infection
12/19/2013	US20130337045 Controlled activation of complement components for use as endogenous adjuvant
12/19/2013	US20130337044 Modulation of effector t cell responses by local depletion of complement component c3
12/19/2013	US20130337039 Internalizing ErBB2 Antibodies
12/19/2013	US20130337018 Antibody therapy for use in the digestive tract
12/19/2013	US20130337014 Compositions and Methods for Controlling Diseases in Animals
12/19/2013	US20130337012 Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers
12/19/2013	US20130337009 Chimeric dna vaccine compositions and methods of use
12/19/2013	US20130337008 Adenoviral vector-based dengue fever vaccine
12/19/2013	US20130337007 Salmonid alphavirus protein e2
12/19/2013	US20130337006 Polyanionic polymer adjuvants for haemophilus influenzae b saccharide vaccines
12/19/2013	US20130337001 Immunogenic composition for treatment of hepatitis C, a method for preparing the composition and use thereof for treating hepatitis C
12/19/2013	US20130337000 Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
12/19/2013	US20130336999 Peptide with reduced dimer formation
12/19/2013	US20130336998 Vaccination in newborns and infants
12/19/2013	US20130336990 Enhancement of the action of anti-infective agents and of central and peripheral nervous system agents and transportation of nucleic acid substances
12/19/2013	US20130336988 Methods for treating early stage or mild neurological disorders
12/19/2013	US20130336985 Medicament and a method for regulation of the vascular tone
12/19/2013	US20130336976 Human immune therapies using a cd27 agonist alone or in combination with other immune modulators
12/19/2013	US20130336970 Compositions and Methods for Treating and Diagnosing Cancer
12/19/2013	US20130336969 Use of olfactomedin-4 protein (olfm4) in colorectal cancer diagnosis
12/19/2013	US20130336968 Pharmaceutical formulation comprising a biopharmaceutical drug
12/19/2013	US20130336966 Coronin 1 modulators for the treatment of autoimmune and lymphoproliferative disorders and mycobacterial infections
12/19/2013	US20130336961 B Cell Depletion for Central Nervous System Injuries and Methods and Uses Thereof
12/19/2013	US20130336960 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
12/19/2013	US20130336959 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
12/19/2013	US20130336958 NOTCH Inhibition In The Treatment Of Cardiovascular Disease
12/19/2013	US20130336927 CULTURING CIRCULAR ssDNA VIRUSES FOR THE PRODUCTION OF VACCINES
12/19/2013	US20130336923 Carbonic Anhydrase IX (G250) Antibodies and Methods of Use Thereof
12/19/2013	US20130336922 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
12/19/2013	US20130336894 Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications
12/19/2013	US20130336886 Tumor specific antibodies and uses therefor
12/19/2013	US20130336885 Anti-lgr5 antibodies and immunoconjugates
12/19/2013	CA2877669A1 Dual receptor antagonistic antigen-binding proteins and uses thereof
12/19/2013	CA2877505A1 Antibodies and conjugates that target misfolded prion protein
12/19/2013	CA2876824A1 Nucleic acids for treatment of allergies
12/19/2013	CA2876796A1 Humanized antibodies to ca215
12/19/2013	CA2876656A1 Cationic lipid vaccine compositions and methods of use
12/19/2013	CA2876636A1 Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies
12/19/2013	CA2876527A1 Inactivated mycobacteria for oral use in the prevention of tuberculosis
12/19/2013	CA2876397A1 Improved antagonist antibodies against gdf-8 and uses therefor
12/19/2013	CA2876393A1 Methylation biomarkers for breast cancer
12/19/2013	CA2876199A1 Compositions and methods for treating cancer
12/19/2013	CA2876196A1 Reassortant btv and ahsv vaccines
12/19/2013	CA2876143A1 Compositions, methods and devices for activating an immune response
12/19/2013	CA2876138A1 Vaccines for serogroup x meningococcus
12/19/2013	CA2876020A1 Polypeptides and antibodies for treating hbv infection and related diseases
12/19/2013	CA2875386A1 Antibody formulation
12/19/2013	CA2875096A1 Anti-pcsk9 antibodies, formulations, dosing, and methods of use
12/19/2013	CA2874761A1 Compositions and methods for non-invasive detection and treatment of hypoxic cells in vivo
12/18/2013	EP2674486A1 Influenza B viruses having alterations in the hemaglutinin polypeptide
12/18/2013	EP2674440A2 Multivalent immunoglobulin-based bioactive assemblies
12/18/2013	EP2674439A1 Anti-TrkA antibodies, derivatives and uses thereof
12/18/2013	EP2674169A1 Polysaccharide immunogens from Clostridium difficile
12/18/2013	EP2674168A1 Modulation of effector T cell responses by local depletion of complement component C3
12/18/2013	EP2674167A1 Controlled activation of complement components for use as endogenous adjuvant
12/18/2013	EP2673635A2 Apoe immunotherapy
12/18/2013	EP2673373A2 Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
12/18/2013	EP2673362A1 B-type plexin antagonists and uses thereof
12/18/2013	EP2673300A1 Hla-restricted, peptide-specific antigen binding proteins
12/18/2013	EP2673298A1 Anti-gb3 antibodies useful in treating disorders associated with angiogenesis
12/18/2013	EP2673294A1 Mutant interleukin-2 polypeptides
12/18/2013	EP2673049A1 Methods of treating macular edema using antiedema therapeutics
12/18/2013	EP2672997A2 Treatment of osteoarthritis and pain
12/18/2013	EP2672996A2 Methods and systems for treating or preventing pregnancy-related hypertensive disorders
12/18/2013	EP2672995A2 Ch2 domain template molecules derived from rational grafting of donor loops onto ch2 scaffolds
12/18/2013	EP2672994A1 Anti-alpha-v integrin antibody for the treatment of prostate cancer
12/18/2013	EP2672993A1 Adjuvant compositions with 4-ibbl
12/18/2013	EP2672992A1 Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same
12/18/2013	EP2672991A1 Yeast-based therapeutic for chronic hepatitis b infection
12/18/2013	EP2672990A1 Antigenic gly1 polypeptide
12/18/2013	EP2672989A1 Immunogenic composition comprising alpha-hemolysin oligopeptides
12/18/2013	EP2672988A1 Antigenic gly1 polypeptides
12/18/2013	EP2470202B1 Clostridial toxins for use in treating premature ejaculation
12/18/2013	EP2246362B1 Polymer conjugates of mutated neublastin
12/18/2013	EP2209804B1 Monoclonal antibody for app
12/18/2013	EP2197918B1 Combination therapy with type i and type ii anti-cd20 antibodies
12/18/2013	EP2165715B1 Therapeutic agent for cancer, and method for treatment of cancer

1 ... 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 ... 1823